IMA
What one share of ImageneBio holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. Our lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (“OX40L”).
ImageneBio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.17 |
|---|---|
| Cash and investments | $11.99 |
| Book value | $12.52 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $66.49 | −$320.06 | $5.54 | −$279.10 | — | −$652.57 |
| 2021 | $22.15 | −$24.38 | $1.26 | −$44.32 | — | $115.57 |
| 2022 | $8.63 | −$38.00 | $0.79 | −$41.75 | — | $81.07 |
| 2023 | $4.39 | −$32.67 | $0.20 | −$38.41 | — | −$52.26 |
| 2024 | $1.45 | −$22.10 | — | −$8.84 | — | −$66.54 |
| 2025 | $0.16 | −$9.64 | — | −$9.82 | — | $27.33 |